Replies to post #170018 on Biotech Values

[DewDiligence]

The salient point is that GILD dropped GS-9669 in phase-3 trials, but has now resurrected GS-9669 in phase-2 trials. GILD clearly has a more positive viewpoint on the utility of a non-nuke in an all-DAA regimen, which is why I said they’re borrowing a page from ABBV/ENTA.